News-Medical.Net August 2, 2024
University of Southern California

A new USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than those with private insurance.

Prescription fills for the drug best known as Ozempic or Wegovy -; semaglutide -; increased by more than 400% between January 2021 and December 2023, according to research out today in JAMA Health Forum.

Approved first for type 2 diabetes, then for weight loss, studies show that semaglutide also improves blood pressure and reduces cardiovascular disease -; problems that plague millions of Americans. Yet the lion’s share of prescriptions went to people with private insurance.

Given the proven cardiovascular benefits of Ozempic and Wegovy when used...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Insurance, Patient / Consumer, Provider, Survey / Study, Trends
Related Articles:
The risk of a bird flu pandemic is rising
Epidemics then and now: Managing loneliness, burnout, and social media toxicity
Patient Portals 4.0: Future of Patient Engagement
AI tool could predict type 2 diabetes 10 years in advance
208 million Americans are classified as obese or overweight, according to new study on 132 data sources

Share This Article